$16.97
0.352.11%
In chiusura: Nov 20, 4:00 PM EST
$17.00
0.030.18%
Post-mercato: Nov 20, 7:57 PM EST

Xeris Biopharma Holdings (XERS) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
| Trimestre fiscale | Data segnalata | EPS effettivo | EPS stimato | Sorpresa% |
|---|---|---|---|---|
| Q3 | Nov 5, 2026 | $0.06 | $0.03 | 100.0 % |
| Q2 | Aug 6, 2026 | $0 | $0.01 | -100.0 % |
| Q1 | May 7, 2026 | $0.01 | $-0.01 | 200.0 % |
| Q4 | Mar 2, 2026 | $0.06 | $0.04 | 50.0 % |
Quarterly Revenue (Billions)
| Trimestre fiscale | Data segnalata | Entrate effettive | Entrate stimate | Sorpresa% |
|---|---|---|---|---|
| Q3 | Nov 5, 2026 | $106.27M | $101.54M | 4.65 % |
| Q2 | Aug 6, 2026 | $92.10M | $90.43M | 1.84 % |
| Q1 | May 7, 2026 | $83.13M | $80.00M | 3.91 % |
| Q4 | Mar 2, 2026 | $85.81M | $84.17M | 1.94 % |
Xeris Biopharma Holdings (XERS) ha pubblicato l'ultima guidance il novembre 5, 2026 per fiscal year 2030. La società ha previsto un fatturato pari a per il periodo.
Rispetto alle previsioni precedenti, Xeris Biopharma Holdings {{epsDirection}} ha modificato le sue previsioni di fatturato da un intervallo precedente di {{epsPriorRange}}.
Xeris Biopharma Holdings ha pubblicato {{revenueDirection}} aggiornamenti delle previsioni tra il {{revenuePriorRange}} e il Xeris Biopharma Holdings. 23
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.03 | $0.01 | $-0.01 | $0.04 |
| Actual | $0.06 | $0.00 | $0.01 | $0.06 |
| Surprise | +100.0% | -100.0% | +200.0% | +50.0% |
| Revenue | ||||
| Estimate | $101.5M | $90.4M | $80.0M | $84.2M |
| Actual | $106.3M | $92.1M | $83.1M | $85.8M |
| Surprise | +4.65% | +1.84% | +3.91% | +1.94% |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E | Q3 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $0.07 | $0.04 | $0.11 | $0.14 |
| Revenue | ||||
| Consensus | $119.0M | $115.6M | — | — |